EMPAGLIFLOZIN MITIGATES CHEMOTHERAPY-INDUCED CARDIOTOXICITY AND ENDOTHELIAL DYSFUNCTION IN BREAST CANCER PATIENTS

Authors:

Abstract:

Empagliflozin has recently been suggested as a potential cardioprotective agent for breast cancer patients undergoing chemotherapy, a treatment known for its cardiotoxic effects. This study evaluated the effects of empagliflozin on diastolic function and endothelial health in breast cancer patients without prior cardiovascular disease. Sixty-six female patients were divided into two groups: one receiving empagliflozin during chemotherapy, and a control group. The study found that patients treated with empagliflozin exhibited significantly better preservation of diastolic function, as evidenced by smaller declines in the E/A ratio, E/e’ ratio, and left ventricular ejection fraction. Additionally, endothelial function, measured by flow-mediated dilation, was less impaired in the empagliflozin group. These results suggest that empagliflozin may effectively mitigate the cardiotoxic and endothelial adverse effects of chemotherapy, offering a novel approach to protecting cardiovascular health in breast cancer patients.

Keywords:

breast cancer cardiotoxicity chemotherapy cardioprotection endothelial dysfunction empagliflozin side effects of chemotherapeutic drugs

References:

1. Anastasiou M, Oikonomou E, Zagouri F, Siasos G, Antonopoulos AS, Psaltopoulou T, et al. Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2017 Dec;70(24):3072. doi: 10.1016/j.jacc.2017.09.1140.
2. Bosman M, Favere K, Neutel CHG, Jacobs G, De Meyer GRY, Martinet W, et al. Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicol Lett. 2021 Aug; 346:23–33. doi: 10.1016/j.toxlet.2021.04.015.
3. Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol [Internet]. 2020;19(1). doi: 10.1186/s12933-020-01147-9 Available from: http://dx.doi.org/10.1186/s12933-020-01147-9.
4. Clayton ZS, Brunt VE, Hutton DA, VanDongen NS, D’Alessandro A, Reisz JA, et al. Doxorubicin-Induced Oxidative Stress and Endothelial Dysfunction in Conduit Arteries Is Prevented by Mitochondrial-Specific Antioxidant Treatment. JACC CardioOncol. 2020 Sep;2(3):475–88. doi: 10.1016/j.jaccao.2020.06.010.
5. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019 Mar;20(3): e175–86. doi:10.1016/S1470-2045(19)30026-9.
6. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–34.
7. Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, et al. Cardiovascular Disease Risk Among Cancer Survivors. J Am Coll Cardiol. 2022 Jul;80(1):22–32. doi: 10.1016/j.jacc.2022.04.042.
8. Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020; 875:173040.
9. Maslova GS, Skrypnyk RІ, Skrypnyk IN. The role of l-ornithine-l-aspartate in prophylaxis of cytostatic-induced liver injury in patients with multiple myeloma. World of Medicine and Biology. 2021; 17(78):100. doi: 10.26724/2079-8334-2021-4-78-100-104.
10. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018 Dec 17;20(12):1690–700. doi: 10.1002/ejhf.1328.
11. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020 Oct 8;383(15):1413–24. doi: 10.1056/NEJMOA2022190.
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan 8;69(1):7–34. doi: 10.3322/caac.21551.

Publication:

«World of Medicine and Biology» Vol. 20 No. 89 (2024) , с. 23-28
УДК 618.19-006.699-08:632.934.3

DOI:

https://doi.org/10.26724/2079-8334-2024-3-89-23-28